High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis

Dig Liver Dis. 2009 Aug;41(8):555-8. doi: 10.1016/j.dld.2008.11.009.

Abstract

Background: The influence of gastritis patterns in Helicobacter pylori eradication rates has been poorly investigated.

Aims: To compare the efficacy of bismuth or proton pump inhibitors triple therapy for H. pylori eradication in pangastritis.

Patients and methods: One hundred and eight patients with pangastritis were assigned to either lansoprazole 30 mg once a day (n=54) or bismuth 240 mg bis in die (n=54) for 14 days combined, for the first week, with amoxicillin 1g plus metronidazole 250 mg tris in die. Eradication was confirmed by (13)C-urea breath test.

Results: With bismuth, successful eradication was observed in 75.9% (41/54) in the intention-to-treat analysis and 78.8% (41/52) in the per-protocol analysis. With lansoprazole, the eradication rates were respectively 46.3% (25/54) and 51.0% (25/49). Bismuth had a significant higher efficacy according to both intention-to-treat analysis (p=0.0029) and per-protocol analysis (p=0.0038) with OR of 3.66 (95% CI: 1.61-8.32) and 3.58 (95% CI: 1.50-8.54) respectively. At regression analysis, the only independent variable affecting eradication was the type of regimen (p=0.026) with an OR of 3.31 (95% CI: 1.16-9.44).

Conclusions: In pangastritis patients, bismuth is more effective than PPI in first-line eradication. For improving the overall eradication rates, an evaluation of gastritis extent might need to be considered.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use
  • Adolescent
  • Adult
  • Aged
  • Amoxicillin / administration & dosage
  • Anti-Infective Agents / therapeutic use*
  • Anti-Ulcer Agents / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Gastritis / drug therapy*
  • Gastritis / microbiology
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / microbiology
  • Helicobacter pylori / drug effects
  • Helicobacter pylori / isolation & purification*
  • Humans
  • Lansoprazole
  • Male
  • Metronidazole / administration & dosage
  • Middle Aged
  • Organometallic Compounds / therapeutic use*
  • Proton Pump Inhibitors / therapeutic use
  • Young Adult

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Infective Agents
  • Anti-Ulcer Agents
  • Organometallic Compounds
  • Proton Pump Inhibitors
  • Lansoprazole
  • Metronidazole
  • Amoxicillin
  • bismuth tripotassium dicitrate